机构名称：
¥ 4.0
EAG: ~35-40% have complement-inhibitor across UK in National PNH Service, most have ravulizumab initially • Eculizumab considered useful particularly in emergency to avoid thrombosis in newly diagnosed people • Renal failure or pregnancy – typically continue eculizumab (limited safety data for ravulizumab/pegcetacoplan) • ~15% remaining anaemic after C5 inhibitor switch to pegcetacoplan（比例正在增加）
iptacopan治疗阵发性夜间血红蛋白尿
主要关键词
相关文件推荐
